HF
VIR icon

HRT Financial’s Vir Biotechnology VIR Stock Holding History

HRT Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-591,648
Closed -$3.57M – 4798
2025
Q4 		$3.57M Buy
591,648
+414,864
+235% +$2.47M 0.01% 955
2025
Q3 		$1.01M Sell
176,784
-5,745
-3% -$29.4K ﹤0.01% 1516
2025
Q2 		$919K Buy
182,529
+166,946
+1,071% +$895K ﹤0.01% 1305
2025
Q1 		$100K Sell
15,583
-68,466
-81% -$609K ﹤0.01% 2148
2024
Q4 		$616K Buy
84,049
+35,027
+71% +$276K ﹤0.01% 1341
2024
Q3 		$367K Buy
49,022
+13,716
+39% +$119K ﹤0.01% 1724
2024
Q2 		$314K Buy
+35,306
New +$339K ﹤0.01% 1491
2024
Q1 		– Sell
-61,095
Closed -$614K – 3156
2023
Q4 		$614K Buy
+61,095
New +$558K ﹤0.01% 1258
2023
Q2 		– Sell
-118,011
Closed -$2.75M – 3341
2023
Q1 		$2.75M Buy
+118,011
New +$3.02M 0.03% 458
2022
Q2 		– Sell
-25,254
Closed -$649K – 3788
2022
Q1 		$649K Buy
+25,254
New +$749K ﹤0.01% 1441
2021
Q3 		– Sell
-20,558
Closed -$971K – 3794
2021
Q2 		$971K Sell
20,558
-33,080
-62% -$1.5M 0.01% 1157
2021
Q1 		$2.75M Buy
+53,638
New +$2.89M 0.03% 467

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

HRT Financial's VIR Position: Q1 2026 in Review

HRT Financial sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 591,648 shares — an estimated $3.57M sold.

HRT Financial first reported a position in VIR in Q1 2021 and held it in 12 quarters. The position peaked at $3.57M in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • HRT Financial reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 591,648 Vir Biotechnology shares in Q1 2026, an estimated $3.57M.
  • HRT Financial first reported a position in Vir Biotechnology in Q1 2021 and held it in 12 quarters.
  • HRT Financial's Vir Biotechnology position peaked at $3.57M in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.